Update from KAITLIN for high-risk HER2-positive early breast cancer
Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA
29 May 2020
Cisplatin plus/minus veliparib in metastatic TNBC and/or germline BRCA-associate...
Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA
29 May 2020
Better genetic diagnostics in Ugandan breast cancer patients
Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA
29 May 2020
COVID-19: Treating breast cancer and the knock on effects of the coronavirus pan...
Prof Stephen Johnston - Royal Marsden NHS Foundation Trust, London, UK
28 May 2020
Pembrolizumab plus chemotherapy for patients with metastatic triple-negative bre...
Dr Javier Cortés - IOB Institute of Oncology, Madrid and Barcelona, Spain
27 May 2020
Perioperative use of NSAIDs reduces risk of early relapse in breast cancer
Dr Michael Retsky - Harvard T.H. Chan School of Public Health, Boston, USA
26 May 2020
Diagnosing, treating and managing breast cancer during COVID-19
Prof Philip Poortmans - University of Antwerp, Antwerp, Belgium
22 May 2020
IMPRIME 1: Combination of pembrolizumab and a novel innate immune activator, Imp...
Dr Steven O'Day - John Wayne Cancer Institute, Santa Monica, USA
19 May 2020
Should breast reconstruction and breast oncoplastic procedures be performed duri...
Dr Raghavan Vidya - The Royal Wolverhampton NHS Trust, Wolverhampton, UK
12 May 2020
I-SPY 2: Durvalumab in combination with olaparib and paclitaxel in high-risk HER...
Prof Lajos Pusztai - Yale Cancer Center, New Haven, USA
5 May 2020
An oncologist's experience of managing breast cancer during the COVID-19 outbrea...
Prof Alessandra Gennari - University Hospital of Novara, Piedmont, Italy
28 Apr 2020
COVID-19: The situation in Peru and managing radiotherapy patients
Dr. Gustavo Sarria – Presidente en Sociedad de Radioterapia del Peru, Lima, Peru
17 Apr 2020
